Prof. Dr. Edeltraut Garbe

Prof. Edeltraut Garbe is a board certified specialist in Internal Medicine (1990) and Clinical Pharmacology (1998). In 2000 she conducted her “Habilitation” (scientific thesis with lecturer qualification) at Charité-Humbold University in Berlin with a pharmacoepidemiologal analysis of ocular side effects of glucocorticoids. Prof. Garbe holds a Master of Science degree in Epidemiology and Biostatistics from McGill University, Montreal (1997), where she has been Part-time Adjunct Professor in the Department of Medicine, Division of Clinical Epidemiology since 2006.
After her residentship in Internal Medicine (1983-1989) at the Central Hospital "Links der Weser" in Bremen she worked from 1990-1997 as Scientific Director in the Department of Experimental and Clinical Pharmacology at the Federal Institute for Drugs and Medical Devices (BfArM) in Berlin. She was Director of the Potsdam Institute of Pharmacoepidemiology and Technology Assessment from 1997 until 2002. In 2002, she followed an appointment from Charité University Hospital Berlin to become Professor of Clinical Pharmacology. During her time at Charité, she established one of the newly founded Pharmacovigilance Centers in Germany which she still chairs.
Since March 2007 she has been Professor of Clinical Epidemiology at the University of Bremen and Head of the Department of Clinical Epidemiology at the Leibniz Institute for Prevention Research and Epidemiology - BIPS. Her scientific focus is on drug safety and she has conducted numerous pharmacoepidemiological studies on the association between drugs and disease outcomes in large healthcare utilization databases and in field-based settings. Prof. Garbe is extraordinary member of the Drug Commission of the German Physicians. She is chairperson of Ethic Board 4 of the State Office for Health and Social Affairs in Berlin and deputy chair of the Ethics Committee of the State Berlin. She is member of the Editorial Board of the journal “Pharmacoepidemiology and Drug Safety” and member of the Advisory Board of the journal “Pharmacopsychiatry”.

    Selected BIPS-Publications

  • Articles with peer review

  • Kersting C, Lindemann C, Jacobi C, LoBaido A, Schneider A, Yurdakul M, Ziegler-Kirbach E, Mikolajczyk R, Garbe E. Therapieziele von Kindern und Jugendlichen mit ADHS und ihren Hauptbezugspersonen. Eine inhaltsanalytische Auswertung und Prüfung der Übereinstimmung zwischen Betroffenen und Bezugspersonen. Das Gesundheitswesen. 2016;78(1):34-36.
  • Douros A, Bronder E, Andersohn F, Klimpel A, Thomae M, Sarganas G, Kreutz R, Garbe E. Drug-induced liver injury: Results from the hospital-based Berlin Case-Control Surveillance Study. British Journal of Clinical Pharmacology. 2015;79(6):988-999.
  • Garbe E, Pigeot I. Der Nutzen großer Gesundheitsdatenbanken für die Arzneimittelrisikoforschung. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2015;58(8):829-837.
  • Hillebrand K, Bricout H, Schulze-Rath R, Schink T, Garbe E. Incidence of herpes zoster and its complications in Germany, 2005-2009. Journal of Infection. 2015;70(2):178-186.
  • Huber M, Andersohn F, Sarganas G, Bronder E, Klimpel A, Thomae M, Konzen C, Kreutz R, Garbe E. Metamizole-induced agranulocytosis revisited: Results from the prospective Berlin Case-Control Surveillance Study. European Journal of Clinical Pharmacology. 2015;712(2):219-227.
  • Mikolajczyk R, Horn J, Schmedt N, Langner I, Lindemann C, Garbe E. Injury prevention by medication among children with attention-deficit/hyperactivity disorder: A case-only study. JAMA Pediatrics. 2015;169(4):391-395.
  • Mor A, Frøslev T, Thomsen RW, Oteri A, Rijnbeek P, Schink T, Garbe E, Pecchioli S, Innocenti F, Bezemer I, Poluzzi E, Sturkenboom MCJM, Trifirò G, Søgaard M. Antibiotic use varies substantially among adults: A cross-national study from five European countries in the ARITMO project. Infection. 2015;43(4):453-472.
  • Ohlmeier C, Hoffmann F, Giersiepen K, Rothgang H, Mikolajczyk R, Appelrath H-J, Elsässer A, Garbe E. Verknüpfung von Routinedaten der Gesetzlichen Krankenversicherung mit Daten eines Krankenhausinformationssystems: Machbar, aber auch "nützlich"? Das Gesundheitswesen. 2015;77(2):e8-e14.
  • Ohlmeier C, Mikolajczyk R, Frick J, Prütz F, Haverkamp W, Garbe E. Incidence, prevalence and one-year all-cause mortality of heart failure in Germany: A study based on electronic healthcare data of more than six million persons. Clinical Research in Cardiology. 2015;104(8):688-696.
  • Schröder C, Schmidt S, Garbe E, Röhmel J, Giersiepen K. Effects of the regular intake of the probiotic Lactobacillus reuteri (DSM 17938) on respiratory and gastrointestinal infections in a workplace setting. A double-blind randomised placebo-controlled trial. BMC Nutrition. 2015;1:3.
  • Douros A, Bronder E, Andersohn F, Klimpel A, Thomae M, Orzechowski H-D, Kreutz R, Garbe E. Flupirtine-induced liver injury - Seven cases from the Berlin Case-Control Surveillance Study and review of the German spontaneous adverse drug reaction reporting database. European Journal of Clinical Pharmacology. 2014;70(4):453-459.
  • Hense S, Hillebrand K, Horn J, Mikolajczyk R, Schulze-Rath R, Garbe E. HPV vaccine uptake after introduction of the vaccine in Germany. Human Vaccines and Immunotherapeutics. 2014;10(6):1729-1733.
  • Hense S, Schink T, Kreisel SH, Marcelon L, Simondon F, Tahden M, Garbe E. Estimation of background incidence rates of Guillain-Barré syndrome in Germany - A retrospective cohort study with electronic healthcare data. Neuroepidemiology. 2014;43(3-4):244-252.
  • Holstiege J, Schink T, Molokhia M, Mazzaglia G, Innocenti F, Oteri A, Bezemer I, Poluzzi E, Puccini A, Ulrichsen SP, Sturkenboom MCJM, Trifirò G, Garbe E. Systemic antibiotic prescribing to paediatric outpatients in 5 European countries: A population-based cohort study. BMC Pediatrics. 2014;14:174.
  • Huber M, Andersohn F, Bronder E, Klimpel A, Thomae M, Konzen C, Meyer O, Salama A, Schrezenmeier H, Hildebrandt M, Späth-Schwalbe E, Grüneisen A, Kreutz R, Garbe E. Drug-induced agranulocytosis in the Berlin Case-Control Surveillance Study. European Journal of Clinical Pharmacology. 2014;70(3):339-345.
  • Jobski K, Enders D, Amann U, Suzart K, Wallander M-A, Schink T, Garbe E. Use of rivaroxaban in Germany: A database drug utilization study of a drug started in hospital. European Journal of Clinical Pharmacology. 2014;70(8):975-981.
  • Ohlmeier C, Frick J, Prütz F, Lampert T, Ziese T, Mikolajczyk R, Garbe E. Nutzungsmöglichkeiten von Routinedaten der Gesetzlichen Krankenversicherung in der Gesundheitsberichterstattung des Bundes. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2014;57(4):464-472.
  • Ohlmeier C, Linder R, Enders D, Mikolajczyk R, Haverkamp W, Horenkamp-Sonntag D, Garbe E. Evaluating methods for intersectoral comparison of quality of care: A routine data analysis of elective percutaneous coronary interventions. Methods of Information in Medicine. 2014;53(4):269-277.
  • Sarganas G, Garbe E, Klimpel A, Hering RC, Bronder E, Haverkamp W. Epidemiology of symptomatic drug-induced long QT syndrome and torsade de pointes in Germany. Europace. 2014;16(1):101-108.
  • Schink T, Holstiege J, Kowalzik F, Zepp F, Garbe E. Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination. Vaccine. 2014;32(6):645-650.
  • Dörks M, Langner I, Behr S, Timmer A, Garbe E. Database study of Lenalidomide (Revlimid®) in Germany: Monitoring off-label use. GMS Medizinische Informatik, Biometrie und Epidemiologie. 2013;9(3):Doc12.
  • Dörks M, Langner I, Dittmann U, Timmer A, Garbe E. Antidepressant drug use and off-label prescribing in children and adolescents in Germany: Results from a large population-based cohort study. European Child & Adolescent Psychiatry. 2013;22(8):511-518.
  • Dörks M, Langner I, Timmer A, Garbe E. Treatment of paediatric epilepsy in Germany: Antiepileptic drug utilisation in children and adolescents with a focus on new antiepileptic drugs. Epilepsy Research. 2013;103(1):45-53.
  • Douros A, Bronder E, Andersohn F, Klimpel A, Thomae M, Ockenga J, Kreutz R, Garbe E. Drug-induced acute pancreatitis: Results from the hospital based Berlin Case-Control Surveillance Study of 102 cases. Alimentary Pharmacology & Therapeutics. 2013;38(7):825-834.
  • Douros A, Kauffmann W, Bronder E, Klimpel A, Garbe E, Kreutz R. Ramipril-induced liver injury: Case report and review of the literature. American Journal of Hypertension. 2013;26(9):1070-1075.
  • Garbe E, Kloss S, Suling M, Pigeot I, Schneeweiss S. High-dimensional versus conventional propensity scores in a comparative effectiveness study of coxibs and reduced upper gastrointestinal complications. European Journal of Clinical Pharmacology. 2013;69(3):549-557.
  • Garbe E, Kreisel SH, Behr S. Risk of subarachnoid hemorrhage and early case fatality associated with outpatient antithrombotic drug use. Stroke. 2013;44(9):2422-2426.
  • Holstiege J, Garbe E. Systemic antibiotic use among children and adolescents in Germany: A population-based study. European Journal of Pediatrics. 2013;172(6):787-795.
  • Horn J, Damm O, Kretzschmar M, Deleré Y, Wichmann O, Kaufmann A, Garbe E, Krämer A, Greiner W, Mikolajczyk R. Estimating the long-term effects of HPV vaccination in Germany. Vaccine. 2013;310(19):2372-2380.
  • Koch J, Wiese-Posselt M, Remschmidt C, Wichmann O, Bertelsmann H, Garbe E, Hengel H, Meerpohl JJ, Mas Marques A, Oppermann H, Hummers-Pradier E, von Kries R, Mertens T. Background paper to the recommendation for routine rotavirus vaccination of infants in Germany. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2013;56:957-984.
  • Kraut A, Langner I, Lindemann C, Banaschewski T, Petermann U, Petermann F, Mikolajczyk R, Garbe E. Comorbidities in ADHD children treated with methylphenidate: A database study. BMC Psychiatry. 2013;13:11.
  • Langner I, Garbe E, Banaschewski T, Mikolajczyk R. Twin and sibling studies using health insurance data: The example of attention deficit/hyperactivity disorder (ADHD). PLOS ONE. 2013;8(4):e62177.
  • Mikolajczyk R, Kraut A, Garbe E. Evaluation of pregnancy outcome records in the German Pharmacoepidemiological Research Database (GePaRD). Pharmacoepidemiology and Drug Safety. 2013;22(8):873-880.
  • Mikolajczyk R, Kraut A, Horn J, Schulze-Rath R, Garbe E. Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany - An ecologic study. Sexually Transmitted Diseases. 2013;40(1):28-31.
  • Mikolajczyk R, Schmedt N, Zhang J, Lindemann C, Langner I, Garbe E. Regional variation in caesarean deliveries in Germany and its causes. BMC Pregnancy and Childbirth. 2013;13:99.
  • Ohlmeier C, Mikolajczyk R, Haverkamp W, Garbe E. Incidence, prevalence, and antithrombotic management of atrial fibrillation in elderly Germans. Europace. 2013;15(10):1436-1444.
  • Schmedt N, Garbe E. Antipsychotic drug use and the risk of venous thromboembolism in elderly patients with dementia. Journal of Clinical Psychopharmacology. 2013;33(6):753-758.
  • Schmidt S, Banaschewski T, Garbe E, Petermann F, Petermann U. Diagnostik der Aufmerksamkeitsdefizit/Hyperaktivitätsstörungen (ADHS) im Kindes- und Jugendalter mit dem K-SADS-PL. Praxis der Kinderpsychologie und Kinderpsychiatrie. 2013;62(7):473-490.
  • Valkhoff VE, Schade R, 't Jong GW, Romio S, Schuemie M, Arfè A, Garbe E, Herings R, Lucchi S, Picelli G, Schink T, Straatman H, Villa M, Kuipers EJ, Sturkenboom MCJM, on behalf of the SOS project consortium. Population-based analysis of non-steroidal anti-inflammatory drug use among children in four European countries. What size of data platforms and which study designs do we need to assess safety issues? The SOS project. BMC Pediatrics. 2013;13:192.
  • Articles without peer review

  • Douros A, Garbe E. Medikamentös induzierte Pankreatitis - Die Berliner Fall-Kontroll-Surveillance-Studie (FAKOS). Bulletin zur Arzneimittelsicherheit. 2014;3(9):3-6.
  • Book chapters

  • Garbe E, Suissa S. Pharmacoepidemiology. In: Ahrens W, Pigeot I, editors. Handbook of epidemiology. 2nd edition. New York: Springer. 2014. S. 1877-1927.

For further publications please follow this link:

The responsibility for the content of this page lies with Edeltraut Garbe.

Edeltraut Garbe


+49 (0)421 218-56-874